NCT03350035View on ClinicalTrials.gov

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 19, 2018

Primary Completion Date

September 18, 2019

Study Completion Date

September 18, 2019

Conditions
Status EpilepticusConvulsive Status EPILEPTICUSNon Convulsive Status EpilepticusEpilepsy
Interventions
DRUG

IV Ganaxolone active

IV

DRUG

IV Placebo, non-active

IV

Trial Locations (8)

15212

Allegheny General Hospital, Pittsburgh

19803

Nemours/AI duPont Hospital for Children, Wilmington

27710

Duke Medical Center, Durham

30303

Grady Hospital, Atlanta

33155

Nicklaus Children's Hospital, Miami

48202

Henry Ford Hospital, Detroit

70121

Oschner Clinic Foundation, New Orleans

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT03350035 - Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus | Biotech Hunter | Biotech Hunter